Literature DB >> 12169237

Mechanisms of antiarrhythmic drug actions and their clinical relevance for controlling disorders of cardiac rhythm.

Uma Srivatsa1, Nitin Wadhani, Bramah N Singh.   

Abstract

This review on antiarrhythmic drugs traces the evolution of the fundamental mechanisms of action of drugs that have been used to control disorders of cardiac rhythm. It describes the very earliest data from experimental studies that dealt with the effects of acute and chronic administration of drugs in whole animals combined with the measurements of the action potential duration and the effective refractory period in isolated tissues. Antiarrhythmic drugs were found to have properties consistent with the block of fast sodium channel conduction, adrenergic blockade, repolarization block, and the block of slow-channel mediated conduction especially in the atrioventricular node. Over the past 15 years, the attention has focused on atrial tissue with atrial fibrillation emerging as the most common arrhythmia in clinical practice. Drug-induced increases in refractoriness as a function rate and in wavelength (product of refractoriness and conduction velocity), and a reduction in numbers of wavelets have been found to be critical in the conversion of atrial fibrillation and maintenance of sinus rhythm. The continued development of newer pharmacologic agents is likely to lead to the resolution of the controversy regarding rhythm versus rate control in various clinical subsets of the arrhythmia by controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12169237     DOI: 10.1007/s11886-002-0040-6

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  41 in total

Review 1.  Adenosine as an antiarrhythmic agent.

Authors:  S L Wilbur; F E Marchlinski
Journal:  Am J Cardiol       Date:  1997-06-19       Impact factor: 2.778

2.  Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart : comparison with amiodarone.

Authors:  W Sun; J S Sarma; B N Singh
Journal:  Circulation       Date:  1999-11-30       Impact factor: 29.690

Review 3.  Comparative mechanisms of action of antiarrhythmic drugs.

Authors:  B N Singh; O Hauswirth
Journal:  Am Heart J       Date:  1974-03       Impact factor: 4.749

4.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

5.  Evolution of diagnostic and interventional cardiac electrophysiology: a brief historical review.

Authors:  G K Feld
Journal:  Am J Cardiol       Date:  1999-11-04       Impact factor: 2.778

6.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence.

Authors:  L M Hondeghem; D J Snyders
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

7.  A focal source of atrial fibrillation treated by discrete radiofrequency ablation.

Authors:  P Jaïs; M Haïssaguerre; D C Shah; S Chouairi; L Gencel; M Hocini; J Clémenty
Journal:  Circulation       Date:  1997-02-04       Impact factor: 29.690

8.  The azimilide post-infarct survival evaluation (ALIVE) trial.

Authors:  A J Camm; R Karam; C M Pratt
Journal:  Am J Cardiol       Date:  1998-03-19       Impact factor: 2.778

9.  The effect of amiodarone, a new anti-anginal drug, on cardiac muscle.

Authors:  B N Singh; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1970-08       Impact factor: 8.739

10.  Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia.

Authors:  D S Ho; R P Zecchin; D A Richards; J B Uther; D L Ross
Journal:  Lancet       Date:  1994-07-02       Impact factor: 79.321

View more
  1 in total

1.  Resveratrol enhances the inotropic effect but inhibits the proarrhythmic effect of sympathomimetic agents in rat myocardium.

Authors:  Jesús Hernandez-Cascales
Journal:  PeerJ       Date:  2017-03-30       Impact factor: 2.984

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.